Microbial diversity and antimicrobial susceptibility in endotracheal tube biofilms recovered from mechanically ventilated COVID-19 patients.
Journal
Biofilm
ISSN: 2590-2075
Titre abrégé: Biofilm
Pays: Netherlands
ID NLM: 101764202
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
20
02
2022
revised:
02
06
2022
accepted:
02
06
2022
pubmed:
21
6
2022
medline:
21
6
2022
entrez:
20
6
2022
Statut:
ppublish
Résumé
In patients with acute respiratory failure, mechanical ventilation through an endotracheal tube (ET) may be required to correct hypoxemia and hypercarbia. However, biofilm formation on these ETs is a risk factor for infections in intubated patients, as the ET can act as a reservoir of microorganisms that can cause infections in the lungs. As severely ill COVID-19 patients often need to be intubated, a better knowledge of the composition of ET biofilms in this population is important. In Spring 2020, during the first wave of the COVID-19 pandemic in Europe, 31 ETs were obtained from COVID-19 patients at Ghent University Hospital (Ghent, Belgium). Biofilms were collected from the ET and the biofilm composition was determined using culture-dependent (MALDI-TOF mass spectrometry and biochemical tests) and culture-independent (16S and ITS1 rRNA amplicon sequencing) approaches. In addition, antimicrobial resistance was assessed for isolates collected via the culture-dependent approach using disc diffusion for 11 antimicrobials commonly used to treat lower respiratory tract infections. The most common microorganisms identified by the culture-dependent approach were those typically found during lung infections and included both presumed commensal and potentially pathogenic microorganisms like
Identifiants
pubmed: 35720435
doi: 10.1016/j.bioflm.2022.100079
pii: S2590-2075(22)00013-2
pmc: PMC9192360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100079Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Frits van Charante reports financial support was provided by Special Research Fund Ghent University. Tom Coenye reports financial support was provided by the European Union Horizon 2020 Marie Skłodowska-Curie Actions program. Given his role as Senior Editor, Tom COENYE had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Akos KOVACS.
Références
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
J Intensive Care. 2021 Jan 18;9(1):10
pubmed: 33461613
Chest. 2021 Aug;160(2):454-465
pubmed: 33857475
mSystems. 2019 Sep 10;4(5):
pubmed: 31506264
Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):61-8
pubmed: 18682995
Lancet Microbe. 2021 Aug;2(8):e354-e365
pubmed: 34100002
J Immunol. 2016 Jun 15;196(12):4839-47
pubmed: 27260767
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
Transl Res. 2012 Oct;160(4):258-66
pubmed: 22683412
Sci Rep. 2016 Nov 04;6:36507
pubmed: 27812037
Int J Med Microbiol. 2010 Nov;300(7):503-11
pubmed: 20510651
Cell Rep. 2019 Feb 19;26(8):2227-2240.e5
pubmed: 30784601
J Clin Microbiol. 1988 Dec;26(12):2544-8
pubmed: 3147992
Eur J Clin Microbiol Infect Dis. 1996 Jul;15(7):607-10
pubmed: 8874082
Crit Care Med. 2010 Apr;38(4):1135-40
pubmed: 20081533
Eur J Clin Microbiol Infect Dis. 2014 Jul;33(7):1101-11
pubmed: 24449346
Intensive Care Med. 1999 Oct;25(10):1072-6
pubmed: 10551961
Semin Perinatol. 2012 Dec;36(6):454-61
pubmed: 23177805
Lancet Microbe. 2020 Jun;1(2):e62
pubmed: 32835331
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Trends Microbiol. 2019 Oct;27(10):850-863
pubmed: 31178124
N Engl J Med. 2013 Jun 13;368(24):2277-85
pubmed: 23697469
Nucleic Acids Res. 2019 Jan 8;47(D1):D259-D264
pubmed: 30371820
Front Med (Lausanne). 2022 Apr 14;9:868954
pubmed: 35492342
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Clin Med (Lond). 2017 Dec;17(6):525-529
pubmed: 29196353
Crit Care Med. 2001 Apr;29(4 Suppl):N64-8
pubmed: 11292878
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
J Clin Microbiol. 1989 Sep;27(9):2014-8
pubmed: 2778064
Pathog Dis. 2017 Apr 1;75(3):
pubmed: 28423168
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Clin Microbiol Infect. 2000 Sep;6(9):509-15
pubmed: 11168187
PLoS One. 2017 Nov 9;12(11):e0187540
pubmed: 29121069
Drug Resist Updat. 2019 May;44:100640
pubmed: 31492517
Front Microbiol. 2019 Jan 31;10:44
pubmed: 30766518
EMBO Mol Med. 2020 Jul 7;12(7):e12560
pubmed: 32453917
BMC Infect Dis. 2022 Mar 2;22(1):207
pubmed: 35236299
Int J Infect Dis. 2022 May;118:197-202
pubmed: 35257905
Trends Microbiol. 2014 Jun;22(6):326-33
pubmed: 24598086
J Infect Chemother. 2020 Jan;26(1):119-123
pubmed: 31300378
Respir Care. 2015 Jan;60(1):21-9
pubmed: 25371399
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Clin Infect Dis. 2002 Mar 1;34(5):634-40
pubmed: 11823954
Clin Chest Med. 2018 Dec;39(4):775-783
pubmed: 30390748
Int J Infect Dis. 2016 Sep;50:10-7
pubmed: 27421818
Nat Microbiol. 2021 Oct;6(10):1245-1258
pubmed: 34465900
Crit Care Med. 2012 May;40(5):1487-98
pubmed: 22511131
J Clin Microbiol. 1986 Jun;23(6):1044-5
pubmed: 3519667
IUBMB Life. 2020 Oct;72(10):2097-2111
pubmed: 32770825
Curr Opin Infect Dis. 2017 Apr;30(2):208-213
pubmed: 28067677
Chest. 2012 Jul;142(1):231-238
pubmed: 22796845
Crit Care. 2020 Jun 29;24(1):382
pubmed: 32600373
Respir Med. 2018 Jan;134:86-91
pubmed: 29413513
PLoS Pathog. 2013 Jan;9(1):e1003057
pubmed: 23326226
MMWR Morb Mortal Wkly Rep. 2009 Oct 2;58(38):1071-4
pubmed: 19798021
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Pathog Dis. 2013 Nov;69(2):142-8
pubmed: 24115610
Microbes Infect. 2020 May - Jun;22(4-5):195-199
pubmed: 32425649
JAMA. 2008 Aug 20;300(7):805-13
pubmed: 18714060
J Bacteriol. 2012 Sep;194(18):4857-66
pubmed: 22753054